Current status of sensor-modulated rate-adaptive cardiac pacing  by Tyers, G. Frank. O.
412
CARDIAC PACING
lACC Vol. 15, No.2
February 1990:412-8
Current Status of Sensor-Modulated Rate-Adaptive Cardiac Pacing
G. FRANK O. TYERS, MD, FRCS(C), FACS, FACC
Vancouver, British Columbia, Canada
In one third of patients requiring permanent cardiac pac-
ing, sinoatrial response to exercise is inadequate. This has
led to the development of a number of nonatriaI sensors
capable of increasing stimulation rate in response to meta-
bolic demand. Initial sensor-modulated pacemakers were
designed for use in the ventricle. This review was under-
taken to compare ventricular rate-adaptive pacing with
dual chamber and nonrate-adaptive atrial modes.
Rate-adaptive ventricular pacing is primarily indicated
in patients with complete heart block and nonfunctional
atria in whom increased rates are not associated with the
development of myocardial ischemia or retrograde conduc-
The capacity to increase rate plays a major role in the ability
of the heart to augment cardiac output. Pacemaker patients
with sinus node disease achieve on average 87% of their
maximal predicted heart rate (I), but approximately one third
of patients attain a maximal atrial rate of <llO beats/min (2),
In some of these latter patients, atrial rate response to activity
is minimal. Other symptomatically bradycardiac patients
present with chronic or recurrent atrial flutter or fibrillation.
Because intrinsic rate adaptation is not possible in some
individuals, a number of atrial-independent, rate-modulating
systems have been developed (3). By far the most commonly
used clinical system to date is vibration-activated piezoelec-
tric crystal, rate-adaptive ventricular pacing (VVI-R). This
review was undertaken to compare the complexity and
effectiveness of VVI-R pacing with pacing modes that pre-
serve atrioventricular (AV) synchrony.
History and Development of
Atrial-Independent Rate-Adaptive Sensors
The objective of rate-adaptive pacing is to optimize
stimulation rate as a function of metabolic demand utilizing
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tion. A responsive atrium remains the best measure of
metabolic demand, and devices capable of maintaining
atrioventricular (AV) sequencing provide superior hemo-
dynamic performance at usual activity levels. In addition,
preserved AV relations reduce the incidence of new atrial
fibrillation and stroke.
Newer devices combining the advantages of atrial and
nonatrial rate modulation with the preservation of AV
synchrony will best utilize the developing sensor technolo-
gies.
(J Am Coil CardioI1990;15:412-8)
a nonatrial marker. Sensors have been categorized as pri-
mary to the effects of increased sympathetic activity or
secondary to the effects of exercise (4-6).
Primary sensors. Potentially measurable primary indica-
tors of metabolic demand include neural activity, blood
catecholamine levels, evoked QT interval, evoked depolar-
ization-repolarization potential, first derivative of ventricu-
lar pressure (dP/dt), pre-ejection interval, contractility and
stroke volume. Only QT devices have been extensively
evaluated. An advantage is the ability to function with a
standard electrocardiographic (EeG) lead. Numerous earlier
problems included over- and undersensing, intermittency,
frequent inappropriate high rate stimulation and drug inter-
actions (3,4,7).
Secondary sensors. Potentially measurable secondary in-
dexes that change as a result of exercise include rate and
volume of respiration, vibration/activity, right atrial pres-
sure, venous blood temperature and pH and oxygen satura-
tion (3-6). Devices using respiration, temperature and vibra-
tion triggers (8-10) are generally available. With appropriate
algorithms, each sensor is capable of inducing rapid «25 s)
and sustained pacing rate increase in response to exercise.
A number of activity sensors have been developed with
piezoelectric transducer detection of vibration established as
highly reliable. As with QT pacers, activity sensing devices
also have the advantage of not requiring a special lead or
sensor external to the pacer. They are, however, nonspecific
with the potential for rapid rates induced by transportation
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system and other nonbiologic vibrations, and pectoral mus-
cle stimulation (11,12). In addition, a vibration sensor cor-
relates only moderately with level of exertion for many
common activities including stair walking and isometrics
(12-14). Return to the heart rate at rest was too rapid relative
to metabolic needs in the postexercise recovery phase with
early designs (12), but recovery algorithms will lessen this
problem in newer devices. Postactivity response will still be
dictated by the pacer circuitry rather than by metabolic
need.
Other secondary sensors also have a degree of exercise
nonspecijicity. For example, nonactivity-related hyperventi-
lation with a respiration-dependent device (15) and hot-tub
immersion or fever in a patient with a temperature-sensing
pacer (9) will result in heart rate acceleration. With an
appropriate algorithm, these responses may be metabolically
appropriate, even though not due to exercise (9).
Atrial sensing devices. An earlier device utilizing atrial
sensing from a bipolar "floating" electrode on the side of the
ventricular lead was designed to stimulate the ventricle
asynchronously at a rate dependent on the average atrial
activity detected (16). Sensing was variable, and electronic
and lead problems were frequent. A promising new device
now in clinical trials uses an improved noncontact electrode
on the side of the ventricular lead for atrially synchronous
ventricular pacing (17).
Advantageous features of nonatrial rate-modulating de-
vices. More experience is required before a definitive
comparative judgment can be made regarding the best
nonatrial rate-modulating mechanisms. Further technical
refinements may eliminate some currently perceived limi-
tations. Reliability, simplicity, low energy consumption,
close correlation with a wide range of activity types and
responsiveness to nonexercise-related variations in meta-
bolic demand (diurnal, fever, anxiety) will be advantageous
features.
Rate-Adaptive Pacer Modes
All single and dual chamber pacing modes may poten-
tially benefit from the addition of nonatrial markers of
metabolic demand. VVI-R units are technically the most
simple and have been widely implanted. AAI-R pacers have
given good results in limited trials (10,18), even though
initially available devices were primarily designed to func-
tion in the ventricle. Although the first rate-modulated dual
chamber pacemakers were problematic (19), several new
DDD-R devices are now entering clinical trials. They are
capable ofappropriately blending their rate response to atrial
or nonatrial control to maximize cardiac output and effi-
ciency.
Indications for Atrial-Independent
Rate-Adaptive Pacing
What are the requirements for and potential patient
benefits of rate-adaptive pacing? The majority of patients
with symptomatic sinus node disease have a satisfactory, if
somewhat less than peak, chronotropic response to meta-
bolic demand. In a study (1) of exercise testing in 24 patients
with sinus node dysfunction who required permanent pac-
ing, an average of 87% of maximal predicted heart rate was
achieved. In another study (2), two thirds of 76 consecutive
patients with sinus node dysfunction achieved atrial rates of
2: 110 beats/min with ambulatory monitoring and bicycle
exercise. Further, these responses were maintained through
4 years of follow-up.
Thus, in many individuals the addition of an adaptive
sensor to a required pacemaker would provide little rate
acceleration benefit. However, in advanced DDD devices, a
nonatrial sensor could assist with discrimination of appro-
priate sinus tachycardia from pathologic intrinsic or pace-
maker-mediated tachycardias (9,19). In over one third of
patients with sinus node disease, with or without complete
heart block, there is a potential need for atrial-independent
rate-modulated pacing (1,2,20).
Comparison of Rate-Adaptive and
Rate-Programmable Ventricular Pacing
In the first large manufacturer-conducted clinical trial (10)
of an activity sensing pacemaker, 54 (24%) of 222 patients
had no meaningful chronotropic response. Average treadmill
exercise time was increased from 9.4 to 10.8 min by pro-
gramming from single chamber demand (VVI/AAI) to single
chamber rate-adaptive modes (VVI-R, AAI-R). Other stud-
ies (8,16,19,21,22) have shown similar modest increases in
treadmill times and work done despite marked increases in
ventricular paced rate and rate-pressure (double) product.
Hemodynamic benefits. In one recent paired, double-
blind randomized study (23) of patients with a clinically
relevant range of ejection fractions, exercise duration in-
creased from 7.5 min in VVI mode at a mean rate of 69
beats/min to 8.4 min in VVI-R mode. Had a faster or
selective VVI rate been used, especially in the patients with
reduced ventricular function, the difference in exercise ca-
pacity might have been less. In patients with relatively
normal ventricular function, oxygen consumption and car-
diac output may not be increased significantly by VVI-R
versus standard VVI pacing (8). At moderate levels of
exercise, cardiac output may even increase more with VVI
pacing at a rate of 70 beats/min or optimal single rapid rate
VVI pacing than with VVI-R pacing (24). Thus, in some
individuals an increase in stroke volume is more effective
and efficient than an increase in rate (3,24). The best rate is
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not necessarily the fastest rate, but rather the lowest rate
achieving the highest cardiac efficiency and output (25).
Risks of standard VVI pacing. Apart from the modest
hemodynamic benefits of VVI-R pacing when compared
with those of rate-programmable VVI pacing, the risks of
standard VVI pacing are present and may be aggravated.
During VVI pacing, the actuarial incidence of new atrial
fibrillation ranges from 20% to 30% in 2 years (26-28). This
is approximately five times the incidence with atrial pacing
and six times that after dual chamber pacing. The incidence
of systemic embolization (26) is six times greater and the
incidence of stroke and congestive heart failure (28) is three
times greater with VVI pacing than with modes that preserve
AV synchrony. The nonhemodynamic benefits of AV syn-
chrony deserve greater emphasis than they have received in
the past.
Rate-Adaptive Ventricular Pacing (VVI-R)
Compared with AV Synchronous Modes
Advantages of dual chamber pacing. Compared with
modes that maintain AV synchrony, VVI-R pacing results in
lower left ventricular performance, stroke volume and car-
diac output. Also, wedge pressure and systemic vascular
resistance are higher (27-32). With ventricular pacing, left
ventricular systolic function is reduced whether or not
preceded by atrial contraction (33). Nevertheless, left ven-
tricular systolic ejection rate is better if ventricular stimula-
tion follows appropriately timed atrial contraction (34).
Further, dual chamber pacing maintains normal AV valvular
function on a long-term basis, whereas AV valvular insuffi-
ciency is seen in substantial numbers of patients during
long-term VVI-R pacing (3,35). Myocardial efficiency and
coronary reserve are highest with atrial, lowest with ventric-
ular and intermediate with dual chamber pacing (34,36).
The improvement in hemodynamics demonstrated shortly
after the institution of AV synchronous pacing not only
persists for years, but also may improve with time (3). In
contrast, the initial improvement in cardiac output with
ventricular pacing tends to be less well maintained. Symp-
toms of congestive heart failure and angina, and signs of
cerebral and renal dysfunction respond much better to
pacing modes that preserve AV synchrony than to ventric-
ular pacing (3). The combination of a mode that preserves
AV synchrony with a rate-adaptive sensor, a more truly
physiologic approach (3), may further reduce the incidence
of new atrial fibrillation even in comparison with the inci-
dence with standard atrial pacing (18,37). This benefit is in
addition to the 3 to 20 times more effective control of
preexisting tachyarrhythmias after institution of atrial or
dual chamber pacing rather than ventricular pacing in pa-
tients with the bradytachycardia syndrome (3,28,38).
At rates >110 beats/min, many patients will achieve a
similar maximal exercise capacity with VVI-R and atrial
synchronous pacing modes (3). However, some individuals
will have very limited or even reduced exercise capacity
with VVI-R pacing (30,31). Also, at the lower levels of
activity where patients spend most of their time (rates in the
70 to 100 beats/min range), stroke volume and cardiac output
improve when AV synchrony is maintained (3,29,30,34).
Duration of the AV Interval in Rate-Adaptive
AV Synchronous Modes
AV interval at high heart rate. High heart rates are by
themselves inotropic (5), and approximately 70% of patients
have similar functional capacity with high rate AVsequential
and high rate ventricular pacing. However, the potential
benefits of dual chamber pacing at high exercise levels may
have been underestimated. In long-term studies (33) of
awake, closed chest animals, an optimally short duration of
the AV interval becomes critical only at high rates. Acute
studies (39,40) of VVI versus AV sequential pacing in
patients with reduced left ventricular function and studies of
patients with implanted dual chamber pacers support the
clinical importance of optimizing the AV interval, particu-
larly at higher heart rates. However, gradual narrowing of
the interval with increasing rate, as occurs naturally (adap-
tive AV delay), was not present in the older dual chamber
pacemakers used in previous studies (3). In addition to
potential benefits to left ventricular systolic function, adap-
tive shortening of the AV delay has a clinical benefit of
essentially eliminating AV block (2 : 1 and so forth) at high
sinus rates. This is due to the accompanying automatic
shortening of the total atrial refractory period.
The full benefits of VVI-R pacing may also not have been
recognized with present devices, which usually have a
maximal upper rate of 150 beats/min. In patients with atrial
fibrillation, but without underlying heart disease, a more
appropriate upper rate limit for a VVI-R pacer appears to be
in the range of 160 to 220 beats/min (41).
Rate-Adaptive Mode Selection in the
Presence of Retrograde Conduction
Risk of tachyarrhythmia and pacemaker syndrome. In
rate-adaptive dual chamber and atrial pacing modes, ventric-
ular stimulation is preceded by atrial depolarization. Thus,
an additional benefit compared with VVI-R pacing is the
potential elimination of the detrimental effects of retrograde
conduction including tachyarrhythmias and the pacemaker
syndrome (3,19,38,42). This condition results in part from
the dramatic fall in cardiac output and blood pressure that
may occur with ventricular pacing in patients who demon-
strate retrograde conduction. Symptoms are probably aggra-
vated by an atrial pressure-moderated reflex that reduces
systemic vascular resistance.
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Figure 1. The relatively narrow range of ven-
tricular pacing rates that produce satisfactory
cardiac output and hemodynamic stability is
illustrated in a 28 year old patient with cardio-
myopathy and complete heart block. Before
pacemaker implantation and after implantation
at standard rates (60 to 72 beats/min), the
patient was incapacitated. After programming
to a rate of 90 beats/min, which the patient
tolerated well for years, heart size was reduced
on chest radiograph, and the patient returned to
work as a tire installer. C.O. == cardiac output
(liters/min); EKG == electrocardiographic heart
rate (beats/min); N.M. == not measured because
of instability; setting == programmed rate of the
pacer (beats/min); S.P. == intraarterial pressure
(mm Hg).
In some patients, retrograde conduction may only be
present during a limited range of ventricular pacing rates,
and the VVI-R mode increases the probability that this
detrimental rate range will be attained at least intermittently.
Also, the VVI-R mode maximizes the duration of pacing
and, thus, the duration of the pacemaker syndrome when
present. However, in patients in whom ventriculoatrial (VA)
conduction is present only at lower rates, the VVI-R exer-
cise response may take the patient outside this range and
avoid continuous VA conduction.
Presentation of pacemaker-mediated tachycardia. Al-
though VA conduction also provides the basis for pacemak-
er-mediated tachycardias, this problem is very infrequent
with present devices because of the availability of exten-
sively programmable atrial refractory period, atrial refrac-
tory extension postpremature ventricular contraction, AV
interval and atrial sensitivity (43). In addition, the develop-
ment and implementation of a number of automatic termina-
tion algorithms limit the clinical significance of the few
attacks that occur (44). In patients who exhibit retrograde
conduction with ventricular pacing, symptomatic control
will generally be better after implantation of an atrial or AV
sequential pacer (3,38,42).
Myocardial Status
Patients with left ventricular dysfunction. In patients with
cardiomyopathy or reduced ventricular function, or both,
the selection of pacing mode may be critical (30). In these
high risk individuals, blood pressure, pulse pressure and
stroke volume may drop quite dramatically with exercise
during VVI-R pacing, compared with relatively normal reo
sponse with atrial and dual chamber pacing. In general, in
patients with reduced myocardial function, cardiac output
increases less with VVI-R than with modes preserving AV
synchrony. In patients with hypertrophic cardiomyopathy,
cardiac output routinely decreases with VVI-R pacing (30).
Effective pacemaker rate. In patients with atrial fibrilla-
tion or atony, reduced ventricular function or cardiomyop-
athy, VVI-R pacing would seem particularly well suited, but
many have a relatively narrow range of rates that yield a
satisfactory cardiac output (3,27,30). These individuals may
achieve a surprisingly high level offunction with a program-
mable VVI pacemaker set within their optimal rate range,
but can be markedly limited by a rate-adaptive pacemaker,
by rates that are too low during rest and too high during
activity (3,25). The narrow range of effective rates in a young
patient with a cardiomyopathy is illustrated in Figure I.
Ischemic Heart Disease
Effects of left ventricular function and ischemia. The
potential risk of using a VVI-R pacer may be highest in
patients with coronary artery disease and symptomatic
bradycardias (30). Natural rhythm and conduction, atrial
pacing and dual chamber pacing all result in more work per
unit of myocardial oxygen consumption than does ventricu-
lar pacing (36). Similarly, increased heart rates due to
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catecholamine stimulation are associated with less myocar-
dial oxygen demand than rapid ventricular pacing. More-
over, regardless of pacing mode and state of the natural
conduction system, there is a rate threshold in patients with
coronary artery disease (usually in the range of tOO beats/
min or less) where myocardial ischemia supervenes. Left
ventricular performance begins to fall associated with in-
creasing ventricular systolic and diastolic volumes and de-
creasing left ventricular ejection fraction (30).
Angina is not a satisfactory safety marker for patients
with coronary artery disease and rate-adaptive pacemakers,
because the detrimental effects on ventricular function and
ECG signs of ischemia usually precede its development. In
some patients, ischemia may always be silent. Evaluation of
noninvasive ejection fraction and appearance of ECG signs
of ischemia should be undertaken in all patients with coro-
nary artery disease to determine the highest permissible rate.
Whether standard or rate adaptive, ventricular pacing should
be avoided if possible (30,36). However, in patients with
associated atrial fibrillation or atony whose primary or drug
related ventricular escape rates are so slow that ischemia
results from the attendant low cardiac output, ventricular
pacing may be the only option. Association vigorous an-
tianginal therapy will usually be required.
Choice of pacemaker mode and rate. In most other pa-
tients with responsive atria and ischemic heart disease, atrial
or dual chamber devices with only limited range rate adap-
tation should be chosen preferentially. If a somewhat faster
than baseline heart rate lessens symptoms and improves
performance without inducing myocardial ischemia, a safe
approach is to implant and program a nontracking device to
the most productive mode and rate below the ischemia
threshold. If possible, in patients with lesser degree or
intermittent heart block, intrinsic conduction should be
preserved by lengthening the AV interval (30,32). This will
avoid the detrimental effects of ventricular stimulation on
myocardial function and efficiency (32,34,36). In summary,
at any heart rate the ischemic potential is always lower with
sinus rhythm or atrial pacing than with AV sequential
pacing. Also, it is always lower with AVsequential than with
ventricular pacing (36).
Sensor Hazards
Sensors hazardous in patients with ischemia. Although
rate-modulated pacing in general and VVI-R pacing in par-
ticular increase the risk of development of myocardial isch-
emia in patients with coronary artery disease, some sensors
may be particularly hazardous (3). Right atrial pressure has
been evaluated as an exercise marker, with a rise in pressure
dictating a rise in pacing rate. However, as a consequence of
ischemia, ventricular function may deteriorate also, leading
to increased atrial pressure. Under these circumstances,
angina could trigger an inappropriate, detrimental increase in
stimulation rate. Similarly, in a patient with a respiration- or
QT interval-modulated pacer, hyperventilation or catechol-
amine release due to chest discomfort could trigger an
increase in rate with the potential for continuing detrimental
positive feedback leading to infarction (7,15). Because rate
increase also shortens the QT interval and chest pain may
lead to further hyperventilation, even an inappropriate rise
in rate could be self-perpetuating. As a complication of
congestive heart failure, inappropriate high rate pacing has
also been reported (45).
Continuous high rate pacing due to activity sensing
pacemakers detecting nonphysiologic vibrations was alluded
to previously, relative to sensor specificity. On a long
turboprop flight or hovercraft trip, this sensor could also lead
to prolonged ischemia, secondary to external vibration-
modulated tachycardia. In patients with coronary artery
disease, few measures are more effective for the induction of
myocardial ischemia, silent or with angina, than the institu-
tion ofrapid VVI-R pacing.
Discussion
Benefits and risks of VVI·R pacing. Rate-adaptive non-
atrial-modulated ventricular pacing has surged in utilization
over the last few years. Commercial data show that VVI-R
units are now the most commonly implanted pacing devices
worldwide. At the other end of the spectrum, some opinion
indicates that potential for benefit is restricted to approxi-
mately 10% of patients (46). Currently, VVI-R pacemakers
are being recommended by some as essentially equivalent to
dual chamber systems (47). This was described by Rickards
(4), one of sensor pacing's pioneers, as "clearly illogical."
Another frequently quoted indication for a VVI-R device is
based on the history of problems with early atrial leads of
inferior design and DDD pacemakers with limited program-
mability. It is implied that rate-adaptive ventricular pacing is
a simplistic concept in keeping with present interests and
capabilities (47). Inability to reliably place atrial leads or
appropriately program DDD units should not be the indica-
tion for a VVI-R device.
This review documents that the subtleties, complexities
and risks of VVI-R pacing are potentially as great as with
DDD pacing. Furthermore, preservation of AV synchrony
significantly decreases morbidity and may improve actuarial
survival versus ventricular demand pacing in patients with
similar preimplant risk profiles (26-28,30,42,48). There is no
evidence to suggest that VVI·R pacing improves survival
versus standard VVI pacing, especially considering the
potentially increased risks of atrial fibrillation, systemic
embolization and myocardial ischemia with a VVI-R device
(48).
Choosing the optimal pacemaker. How can the optimal
device and sensing mechanism be chosen? There are pa-
tients with a range of ventricular function, complete heart
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block, absence of coronary artery disease, and persistent
pathologic atrial rhythms where VVI-R pacing represents
the best alternative (49). If cardiac output increases as a
function of ventricular pacing rate, these individuals have a
significantly better functional performance with exercise if a
VVI-R, instead of a VVI device, is implanted.
In contrast, the majority of patients have metabolically or
electrically responsive atria and should be afforded the many
benefits of appropriate AV sequencing. Standard atrial,
AAI-R, DDD, DDD-R and DVUDDI-R are the modes pro-
viding the highest potential benefit and lowest potential risk.
Several devices now in clinical trials provide programmable
selection of all of these modes plus VVI-R, should chronic
atrial fibrillation or flutter supervene. When all possible
pacing modes are considered, rate adaptive mechanisms
may in the future prove to be of benefit in over 40% of
patients requiring a pacemaker (20).
Conclusions. Rate-modulated ventricular pacing will be
most consistently beneficial in patients without retrograde
conduction who have nonfunctional atria and whose ventri-
cles respond to rate increase by progressively increasing
cardiac output without the development of ischemia. For
patients with atria that can be stimulated, hemodynamic
benefits are potentially denied and risks may be unnecessar-
ily increased by the implantation of a single chamber, rate-
adaptive ventricular pacemaker that does not preserve AV
synchrony. However, because the atrium is quite frequently
an unreliable indicator of metabolic demand, the application
of sensor technologies to atrial and dual chamber pacing and
tachyarrhythmia control devices holds great promise.
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